Scholarlink

Background and aim <p>Salivary nitrite (SNO<sub>2</sub>), a marker of oral nitrate-reducing capacity and nitric oxide (NO) bioavailability, often impaired in type 2 diabetes (T2DM). This study aimed to investigate the associations between SNO<sub>2</sub> concentration, and metabolic, vascular, and renal parameters in patients with T2DM.</p> Methods <p>Sixty-four adults with T2DM (53.9 ± 7.2 years, 45.3% men, diabetes duration 8.3 ± 6.2 years) participated in this cross-sectional study. Salivary NO<sub>2</sub> concentrations, glycemic parameters, blood pressure (BP) indices, renal function, lipid profiles, liver function, and systemic NO metabolites were measured. Participants with high- and low-SNO<sub>2</sub> (&lt; and ≥ 69.3 µmol/L) were compared for cardiometabolic parameters.</p> Results <p>Compared with the low-SNO<sub>2</sub> group, participants with higher SNO<sub>2</sub> had lower HbA1c (6.2% vs. 6.9%, <i>P</i> = 0.040), fasting insulin (6.1 vs. 8.2 µU/mL, <i>P</i> = 0.007), HOMA-IR (2.1 vs. 3.3, <i>P</i> = 0.003), and C-peptide (1.3 vs. 1.7 ng/mL, <i>P</i> = 0.023), with higher QUICKI (0.34 vs. 0.32, <i>P</i> = 0.003). Fasting serum glucose was marginally lower (142 vs. 167&#xa0;mg/dL, <i>P</i> = 0.069) in the high- compared to the low-SNO<sub>2</sub> group. Median serum nitric oxide metabolites (NOx) concentrations were higher in the high-SNO<sub>2</sub> group (51.1 vs. 29.1 µmol/L, <i>P</i> = 0.015). Salivary nitrate (NO<sub>3</sub>) (694 vs. 463 µmol/L, <i>P</i> = 0.035) and NO<sub>2</sub> (153 vs. 20.6, <i>P</i> = 0.001) were also higher in the high- compared to low-SNO<sub>2</sub> group. No significant difference was observed in BP measures, lipid profile, and liver and renal function test across groups.</p> Conclusions <p>High-SNO<sub>2</sub> levels were associated with greater glycemic control, insulin sensitivity, and NO bioavailability in patients with T2DM.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Higher salivary nitrite is associated with improved glycemic control and insulin sensitivity in patients with type 2 diabetes

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月5日

查看全文
  • Zahra Bahadoran,
  • Reza Norouzirad,
  • Sajad Jeddi,
  • Asghar Ghasemi

摘要

Background and aim

Salivary nitrite (SNO2), a marker of oral nitrate-reducing capacity and nitric oxide (NO) bioavailability, often impaired in type 2 diabetes (T2DM). This study aimed to investigate the associations between SNO2 concentration, and metabolic, vascular, and renal parameters in patients with T2DM.

Methods

Sixty-four adults with T2DM (53.9 ± 7.2 years, 45.3% men, diabetes duration 8.3 ± 6.2 years) participated in this cross-sectional study. Salivary NO2 concentrations, glycemic parameters, blood pressure (BP) indices, renal function, lipid profiles, liver function, and systemic NO metabolites were measured. Participants with high- and low-SNO2 (< and ≥ 69.3 µmol/L) were compared for cardiometabolic parameters.

Results

Compared with the low-SNO2 group, participants with higher SNO2 had lower HbA1c (6.2% vs. 6.9%, P = 0.040), fasting insulin (6.1 vs. 8.2 µU/mL, P = 0.007), HOMA-IR (2.1 vs. 3.3, P = 0.003), and C-peptide (1.3 vs. 1.7 ng/mL, P = 0.023), with higher QUICKI (0.34 vs. 0.32, P = 0.003). Fasting serum glucose was marginally lower (142 vs. 167 mg/dL, P = 0.069) in the high- compared to the low-SNO2 group. Median serum nitric oxide metabolites (NOx) concentrations were higher in the high-SNO2 group (51.1 vs. 29.1 µmol/L, P = 0.015). Salivary nitrate (NO3) (694 vs. 463 µmol/L, P = 0.035) and NO2 (153 vs. 20.6, P = 0.001) were also higher in the high- compared to low-SNO2 group. No significant difference was observed in BP measures, lipid profile, and liver and renal function test across groups.

Conclusions

High-SNO2 levels were associated with greater glycemic control, insulin sensitivity, and NO bioavailability in patients with T2DM.